A Phase 3 interventional study of Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) and Sham treatment in Retinal Vein Occlusion, sponsored by Bayer. Completed at 73 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-03.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing aflibercept in Retinal Vein Occlusion — none open to participants now, none under way, none of them phase 3. aflibercept · Retinal Vein Occlusion.
Among the 21 studies testing aflibercept in Retinal Vein Occlusion, this one is the 4th largest by enrollment, is one of 2 that started in 2009, is one of 4 in phase 3, and was the 2nd registered.
289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.
Browse Retinal Vein Occlusion studies →None of the 21 studies testing aflibercept in Retinal Vein Occlusion is open now. The open studies under Retinal Vein Occlusion, anywhere →
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 4 · Phase 4 10
First in 2009; this study’s year is marked. 2 started in 2009.
This study's enrollment of 177 is above the median of 51 across 208 interventional studies indexed under Retinal Vein Occlusion.
Median enrollment 56 across the 21 interventional studies. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 21 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 9 studies filed under Retinal Vein Occlusion — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing aflibercept in Retinal Vein Occlusion, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine the efficacy of vascular endothelial growth factor (VEGF) Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20, later as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Follow-up phase: Participants on IAI, who continued the study, received 2 mg dose of IAI depending on the study retreatment criteria at Week 60 and 68.
Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) · Other: Sham treatment
Participants received sham treatment administered every 4 weeks from Day 1 through Week 52. Follow-up phase: Participants on sham treatment, who switched to Intravitreal Aflibercept Injection (IAI), received a 2 mg dose of IAI at week 52 and depending on the study retreatment criteria at Week 60 and 68.
Other: Sham treatment
Intravitreal injection. Weeks 0 to 20 of Aflibercept Injection every 4 weeks; Weeks 24 to 52 every 4 weeks PRN (pro re nata, on demand); plus additional on Week 60 and 68.
Sham treatment. Weeks 0 to 52 sham treatment every 4 weeks; plus additional on Week 60 and 68.
Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants Before Week 24 Evaluated as Failures
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
Time frame: Baseline and Week 24
Change From Baseline in BCVA as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 24 - Last Observation Carried Forward (LOCF)
Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. However, because this was assessed at the screening visit, subjects may have had a higher BCVA recorded at the baseline visit and would not have been excluded from the study.
Time frame: Baseline and Week 24
Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF
Time frame: Baseline and Week 24
Percentage of Participants Who Developed Neovascularization During the First 24 Weeks
Formation of blood vessels in the anterior segment, optic disc, or elsewhere in the fundus up to Week 24
Time frame: From baseline until Week 24
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 24 - LOCF
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight
Time frame: Baseline and Week 24
Change From Baseline in European Five-dimensional Health Scale (EQ-5D) Score at Week 24 - LOCF
EQ-5D is a quality of life questionnaire based on a scale from -0.594 (worst) to 1.00 (best).
Time frame: Baseline and Week 24
| Milestone | Aflibercept Injection First, Then Aflibercept Injection | Sham Treatment First, Then Aflibercept Injection |
|---|---|---|
| Started | 106 | 71 |
| Participants received treatment | 104 | 68 |
| Fulfilled requirements of fas population | 103 | 68 |
| Completed week 24, from fas | 97 | 57 |
| Completed week 52, from fas | 91 | 52 |
| Completed | 90 | 52 |
| Not completed | 16 | 19 |
| Withdrew: Adverse event | 5 | 5 |
| Withdrew: Lack of efficacy | 0 | 5 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: (overseas travel - indefinite period) | 1 | 0 |
| Withdrew: Increase in vis. acuity, never injected | 0 | 1 |
| Withdrew: Protocol violation | 5 | 2 |
| Withdrew: Withdrawal by subject | 4 | 6 |
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
| Percentage of participants | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Sham Treatment |
|---|---|---|
| Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants Before Week 24 Evaluated as Failures | 60.2 | 22.1 |
Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. However, because this was assessed at the screening visit, subjects may have had a higher BCVA recorded at the baseline visit and would not have been excluded from the study.
| Letters correctly read | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Sham Treatment |
|---|---|---|
| Change From Baseline in BCVA as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 24 - Last Observation Carried Forward (LOCF) | 71.6 ± 17.1 | 54.3 ± 20.2 |
| microns | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Sham Treatment |
|---|---|---|
| Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF | -448.58 ± 256.02 | -169.27 ± 224.72 |
Formation of blood vessels in the anterior segment, optic disc, or elsewhere in the fundus up to Week 24
| Percentage of participants | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Sham Treatment |
|---|---|---|
| Any neovascularization | 2.9 | 4.4 |
| Anterior segment neovascularization | 1.9 | 1.5 |
| Neovascularization of the optic disc (NVD) | 0.0 | 0.0 |
| Neovascularization elsewhere in the fundus (NVE) | 1.0 | 2.9 |
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight
| Scores on a scale | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Sham Treatment |
|---|---|---|
| Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 24 - LOCF | 7.46 ± 9.55 | 3.55 ± 9.74 |
EQ-5D is a quality of life questionnaire based on a scale from -0.594 (worst) to 1.00 (best).
| Scores on a scale | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Sham Treatment |
|---|---|---|
| Change From Baseline in European Five-dimensional Health Scale (EQ-5D) Score at Week 24 - LOCF | 0.029 ± 0.139 | -0.002 ± 0.195 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept Injection (Until Week 20) | — | 8/104 (7.7%) | 52/104 (50%) |
| Sham Treatment (Until Week 20) | — | 8/68 (11.8%) | 44/68 (64.7%) |
| Aflibercept Injection (Until Week 48) | — | 14/97 (14.4%) | 66/97 (68%) |
| Sham Treatment (Until Week 48) | — | 7/57 (12.3%) | 30/57 (52.6%) |
| Aflibercept Injection Continued (Until Week 68) | — | 4/91 (4.4%) | 38/91 (41.8%) |
| Sham Treatment Then Aflibercept Injection (Until Week 68) | — | 3/52 (5.8%) | 19/52 (36.5%) |
| Event | Aflibercept Injection (Until Week 20) | Sham Treatment (Until Week 20) | Aflibercept Injection (Until Week 48) | Sham Treatment (Until Week 48) | Aflibercept Injection Continued (Until Week 68) | Sham Treatment Then Aflibercept Injection (Until Week 68) |
|---|---|---|---|---|---|---|
| Macular oedemaEye disorders | 0/104 | 2/68 | 4/97 | 0/57 | 1/91 | 0/52 |
| SyncopeNervous system disorders | 0/104 | 0/68 | 1/97 | 2/57 | 0/91 | 0/52 |
| Visual acuity reducedEye disorders | 0/104 | 1/68 | 1/97 | 0/57 | 2/91 | 0/52 |
| Aortic valve incompetenceCardiac disorders | 0/104 | 0/68 | 0/97 | 0/57 | 0/91 | 1/52 |
| Cardiac failureCardiac disorders | 0/104 | 0/68 | 0/97 | 0/57 | 0/91 | 1/52 |
| Coronary artery stenosisCardiac disorders | 0/104 | 0/68 | 0/97 | 0/57 | 0/91 | 1/52 |
| Diastolic dysfunctionCardiac disorders | 0/104 | 0/68 | 0/97 | 0/57 | 0/91 | 1/52 |
| Mitral valve incompetenceCardiac disorders | 0/104 | 0/68 | 0/97 | 0/57 | 0/91 | 1/52 |
| Femur fractureInjury, poisoning and procedural complications | 0/104 | 0/68 | 0/97 | 0/57 | 0/91 | 1/52 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 0/104 | 0/68 | 0/97 | 0/57 | 0/91 | 1/52 |
| Event | Aflibercept Injection (Until Week 20) | Sham Treatment (Until Week 20) | Aflibercept Injection (Until Week 48) | Sham Treatment (Until Week 48) | Aflibercept Injection Continued (Until Week 68) | Sham Treatment Then Aflibercept Injection (Until Week 68) |
|---|---|---|---|---|---|---|
| Macular oedemaEye disorders | 2/104 | 9/68 | 30/97 | 7/57 | 17/91 | 2/52 |
| NasopharyngitisInfections and infestations | 8/104 | 6/68 | 10/97 | 11/57 | 4/91 | 2/52 |
| Intraocular pressure increasedInvestigations | 9/104 | 4/68 | 14/97 | 2/57 | 2/91 | 1/52 |
| Eye painEye disorders | 12/104 | 3/68 | 6/97 | 2/57 | 1/91 | 0/52 |
| Retinal haemorrhageEye disorders | 4/104 | 6/68 | 11/97 | 5/57 | 5/91 | 2/52 |
| Retinal vascular disorderEye disorders | 6/104 | 7/68 | 10/97 | 2/57 | 0/91 | 2/52 |
| Visual acuity reducedEye disorders | 2/104 | 7/68 | 10/97 | 1/57 | 7/91 | 1/52 |
| Eye irritationEye disorders | 3/104 | 7/68 | 4/97 | 1/57 | 1/91 | 2/52 |
| Conjunctival haemorrhageEye disorders | 10/104 | 3/68 | 3/97 | 0/57 | 9/91 | 3/52 |
| Retinal exudatesEye disorders | 8/104 | 5/68 | 4/97 | 3/57 | 0/91 | 0/52 |
| Age, Continuous(Years) | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Sham Treatment | Total |
|---|---|---|---|
| Mean | 60.0 ± 12.3 | 63.8 ± 13.3 | 61.5 ± 12.8 |
| Sex: Female, Male(Participants) | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Sham Treatment | Total |
|---|---|---|---|
| Female | 45 | 31 | 76 |
| Male | 59 | 37 | 96 |
| Ethnicity (NIH/OMB)(Participants) | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Sham Treatment | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 1 | 5 |
| Not Hispanic or Latino | 100 | 66 | 166 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Baseline Best Corrected Visual Acuity (BCVA) letter scores(Letters correctly read) | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Sham Treatment | Total |
|---|---|---|---|
| Mean | 53.5 ± 15.7 | 50.9 ± 15.4 | 52.5 ± 15.6 |
| Number of participants with baseline retinal perfusion(Participants) | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Sham Treatment | Total |
|---|---|---|---|
| Perfused | 90 | 54 | 144 |
| Nonperfused | 7 | 7 | 14 |
| Indeterminate | 7 | 7 | 14 |
| Baseline Retinal Thickness by Optical Coherence Tomography (OCT)(microns) | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Sham Treatment | Total |
|---|---|---|---|
| Mean | 682.78 ± 233.36 | 638.66 ± 224.69 | 665.34 ± 230.33 |
| Baseline intraocular pressure(mm Hg) | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Sham Treatment | Total |
|---|---|---|---|
| Mean | 15.2 ± 2.8 | 14.4 ± 2.7 | 14.9 ± 2.8 |
| Number of participants with time since Central retinal vein occlusion (CRVO) diagnosis(Participants) | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Sham Treatment | Total |
|---|---|---|---|
| >= 2 months | 46 | 33 | 79 |
| < 2 months | 56 | 35 | 91 |
| Missing | 2 | 0 | 2 |
3 further baseline measures are reported on the registry.
The record gives a start of Oct 2009, a primary completion of Feb 2011 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 1 year 9 months after primary completion. A results delay was requested in Jan 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept